PARP in vivo Pharmacodynamic Assay IIaccurately measures net PAR levels in cellular extracts and has been used to document differences in PAR levels in human tumor lysates from a variety of tissues, organs, and xenografts with a sensitivity of 2 pg/ml.
PARP catalyzes the NAD-dependent addition of poly (ADP-ribose) (PAR) onto itself and adjacent nuclear proteins. PARP-1 is regarded as a promising target for the development of drugs useful in various regimens of cancer therapy, inflammation, ischemia and neurodegeneration. More recently the discovery that breast cancers deficient in homologous recombination are sensitive to nontoxic PARP inhibitors has resulted in efforts by numerous pharmaceutical companies to develop PARP-1 specific drugs.
Trevigen's PARP in vivo Pharmacodynamic Assay uses a validated sample processing regimen and a chemiluminescent, plate-based (96 wells) sandwich ELISA format that accurately reports PAR levels in lysates with a sensitivity of 2 pg/ml and a linear dynamic range to 1,000 pg/ml.
Applications
|
| Quantification of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from various tissues, organs and xenografts. |
|
|
Monitoring the efficacy of PARP inhibitors on cellular PAR formation.
|
|
|
Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.
|
Description
|
Size
|
Cat. #
|
HT PARP in vivo Pharmacodynamic Assay II
|
96 Samples
|
|
|
|
|
沒有留言:
張貼留言